Gilead Sciences Inc.
Gilead Sciences Completes Acquisition of Arcellx
Summary
Gilead Sciences, Inc. has completed its acquisition of Arcellx, Inc. for $115 per share in cash and one contingent value right (CVR) of $5 per share, totaling approximately $7.8 billion. The acquisition provides Gilead with full control of an investigational BCMA-directed CAR T-cell therapy for multiple myeloma, anitocabtagene autoleucel (anito-cel). The transaction is expected to reduce Gilead's GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67, with modest dilution in 2026 and 2027, and accretion thereafter, subject to FDA approval of anito-cel.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement